Brought to you by 
Pharmasset, Roche enter hepatitis C agreement
Nov 2004
Executive Summary
Antiviral drug development company Pharmasset licensed F. Hoffman-La Roche worldwide rights (except in Latin America and Korea) to develop the nucleoside polymerase inhibitor PSI-6130 and its prodrugs for hepatitis C virus (HCV).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharmasset, Roche enter hepatitis C agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice